BCLAF1: Function in Apoptosis, Cancer, and Viral Infection

BCLAF1, short for B-cell lymphoma-2-associated transcription factor 1, is a protein that sits at the intersection of several processes critical to human health: programmed cell death, cancer development, the body’s response to DNA damage, and defense against viral infections. It was originally identified through its connection to apoptosis, the cell’s self-destruction program, but research over the past two decades has revealed it to be far more versatile than that early label suggested. Depending on the tissue, the disease, and the molecular context, BCLAF1 can act as a guardian that helps cells die when they should or as a rogue factor that helps tumors survive and resist treatment.

Origins in Apoptosis

BCLAF1 earned its name because it was first discovered through its interaction with members of the Bcl-2 family, a group of proteins best known for controlling whether a cell lives or dies. Bcl-2 itself is anti-apoptotic, meaning it blocks cell death. BCLAF1 was found to counteract that survival signal, nudging cells toward apoptosis when circumstances warrant it. In healthy tissue, this is a good thing: cells that accumulate too much damage or start growing out of control need a mechanism that forces them to shut down, and BCLAF1 is part of that safety net.

The apoptosis connection turns out to be just one layer of BCLAF1’s involvement in cell death pathways. Research on myeloma cells has shown that BCLAF1 can also trigger autophagy, a process in which cells digest their own components. BCLAF1 induces autophagy by displacing a key protein called Beclin-1 from the Bcl-2 complex. In myeloma cells, this autophagy-promoting function is kept in check by caspase-10, an enzyme that cleaves and inactivates BCLAF1, preventing runaway autophagic cell death.¹ The balance between these forces matters: too much BCLAF1-driven autophagy can kill cells that should survive, while too little can let damaged cells persist when they should not.

Keeping the Genome Intact

Every cell in the body faces a constant barrage of DNA damage from radiation, chemical exposure, and normal metabolic byproducts. When double-strand breaks occur in DNA, the cell has two main repair strategies. BCLAF1 participates in both of them, though through different molecular partnerships.

In one pathway, BCLAF1 physically interacts with a protein called γH2AX at the sites of DNA breaks. It helps stabilize a complex of repair proteins that carry out non-homologous end joining, which essentially glues broken DNA ends back together. This repair mechanism is especially important after exposure to ionizing radiation.² In the other pathway, BCLAF1 partners with a protein called BACH1 and is recruited to damage sites in a process that depends on BRCA1, a gene widely known for its role in breast cancer susceptibility. Cells lacking BCLAF1 are deficient in homologous recombination, the more precise of the two repair strategies.³

This dual involvement in both repair pathways helps explain why BCLAF1’s role in cancer is so complex. A protein that keeps DNA intact is, at first glance, a tumor suppressor. But the same DNA repair capacity can protect cancer cells from the damage inflicted by radiation therapy or chemotherapy, which is exactly what researchers have observed in certain aggressive tumors.

RNA Processing and Splicing

Beyond its nuclear duties at DNA damage sites, BCLAF1 plays a significant role in how cells process their genetic instructions after DNA is copied into RNA. Working alongside a partner called THRAP3, BCLAF1 selectively regulates the splicing and export of a specific subset of messenger RNA transcripts, many of which are themselves involved in the DNA damage response.⁴ In other words, BCLAF1 does not just show up at broken DNA; it also controls which repair tools the cell produces in the first place.

More recently, work in acute myeloid leukemia cells has shown that BCLAF1 physically associates with the core machinery of the spliceosome and has a particularly strong effect on a phenomenon called intron retention, where segments of RNA that are normally removed get left in.⁵ Intron retention can dramatically change which proteins a cell makes and in what quantities. When BCLAF1 levels shift, the downstream effects ripple across the cell’s protein landscape, altering everything from metabolic adaptation to stress responses.

A Dual Identity in Cancer

One of the most striking features of BCLAF1 biology is that it does not play a single, consistent role across different cancers. In some tumor types, it acts as a tumor suppressor; in others, it promotes tumor growth, drug resistance, and metastasis. The cellular context and the type of cancer determine which face it shows.⁶

The tumor-promoting side is especially well documented in liver cancer. In hepatocellular carcinoma, BCLAF1 expression is elevated in tumor tissue compared to surrounding healthy tissue. High BCLAF1 levels correlate with higher tumor grades and worse survival outcomes.⁷ Mechanistically, BCLAF1 promotes liver cancer cell proliferation and invasion by directly binding to the promoter of a long non-coding RNA called NEAT1 and boosting its expression. It also drives resistance to the chemotherapy drug 5-fluorouracil by upregulating drug-efflux pumps in the cancer cells.⁸ In a separate mechanism, BCLAF1’s interaction with the chaperone protein Hsp90α stabilizes BCLAF1 itself, and that stabilized BCLAF1 then protects the mRNA of the oncogene c-MYC from degradation, further fueling tumor growth.⁹

A similar tumor-promoting pattern appears in adrenocortical carcinoma, where high BCLAF1 expression is significantly correlated with poor prognosis and reduced survival.¹⁰ And in bladder cancer, a long non-coding RNA called PVT1 acts as a molecular sponge that soaks up a microRNA that would normally suppress BCLAF1. When PVT1 absorbs that microRNA, BCLAF1 levels rise, accelerating the growth and spread of bladder cancer cells.¹¹

Radioresistance in Triple-Negative Breast Cancer

Triple-negative breast cancer is one of the most difficult subtypes to treat because it lacks the receptors that most targeted therapies exploit. Radiation therapy is a mainstay of treatment, but some tumors develop resistance to it. Recent research has identified BCLAF1 as a driver of that radioresistance. In radiation-resistant breast cancer cells, BCLAF1 protein levels are elevated compared to non-resistant counterparts. Overexpressing BCLAF1 in parental breast cancer cells reduced their sensitivity to radiation, and BCLAF1 expression correlated positively with DNA repair gene signatures in patient tumor data.¹²

The same study revealed something more troubling: BCLAF1 sustains cancer stem cell properties in these resistant tumors. When researchers knocked down BCLAF1 in radiation-resistant cells, key stem cell factors dropped, and the cells lost much of their ability to form tumorspheres, a laboratory measure of stem-like behavior. Cancer stem cells are widely thought to be responsible for tumor recurrence after treatment, so BCLAF1’s role in maintaining them has direct implications for whether these cancers come back after radiation.

Immunotherapy Resistance

The connection between BCLAF1 and treatment resistance extends beyond radiation and chemotherapy. In hepatocellular carcinoma, elevated BCLAF1 causes accumulation of HIF-1α, a protein normally associated with low-oxygen conditions, even under normal oxygen levels. This abnormal HIF-1α buildup enhances resistance to PD-L1-targeted immunotherapy, one of the most promising recent advances in cancer treatment.⁷ The mechanism involves BCLAF1 forming a complex with CUL3, a component of the cell’s protein-disposal system. This is a particularly concerning finding because immunotherapy has become a frontline option for advanced liver cancer, and understanding why some patients do not respond is one of the field’s most pressing questions.

How Viruses Exploit BCLAF1

BCLAF1’s role in the immune system makes it a natural target for viruses looking to disable host defenses. The evidence is clearest for herpesviruses, which have evolved distinct strategies to neutralize BCLAF1 at different stages of infection.

Human cytomegalovirus, which infects a majority of adults worldwide and poses particular dangers to immunocompromised patients and developing fetuses, attacks BCLAF1 almost immediately upon entering a cell. Viral proteins called pp71 and UL35, which are packaged inside the virus particle and delivered directly into the cell upon infection, direct the rapid destruction of BCLAF1 through the cell’s own protein-disposal system.¹³ The speed of this attack is telling: the virus treats BCLAF1 as an immediate threat that must be eliminated before the cell can mount an effective defense.

Alphaherpesviruses, including herpes simplex virus type 1 and pseudorabies virus, use a different viral protein, US3, to degrade BCLAF1. Research has shown that BCLAF1 is a critical regulator of the type I interferon response, one of the body’s earliest and most potent antiviral defenses. By eliminating BCLAF1, these viruses effectively blind the cell’s alarm system.¹⁴ The fact that multiple virus families have independently evolved mechanisms to destroy the same host protein strongly suggests that BCLAF1 is a genuine bottleneck in antiviral immunity, not a bystander.

Splicing as a Therapeutic Target

The discovery that BCLAF1 exists in multiple splice variants, and that some variants are more dangerous than others, has opened a potential avenue for drug development. In metastatic colorectal cancer, a splicing regulator called SRSF10 is overexpressed and drives production of a pro-tumorigenic long form of BCLAF1 known as BCLAF1-L. Researchers identified a class of small molecules built around an aminothiazole carboxamide core that reduce BCLAF1-L production. Two of these compounds, GPS167 and GPS192, achieved half of their maximal splicing effect at concentrations of roughly 2 micromolar. GPS167 impaired the growth of colorectal cancer cell lines and organoids, blocked colony formation and cell migration, and promoted cell death in a manner dependent on both SRSF10 and the tumor suppressor p53. Crucially, the compound had minimal effects on normal colon cells and normal colorectal organoids.¹⁵

This selectivity is significant. One of the persistent challenges in cancer therapy is killing tumor cells without destroying healthy tissue. An approach that shifts BCLAF1 splicing rather than eliminating the protein entirely could, in theory, preserve BCLAF1’s beneficial functions in DNA repair and immune defense while disrupting the specific splice variant that fuels tumor growth. The research is still preclinical, but it represents an increasingly sophisticated way of thinking about BCLAF1 as a drug target: not as a single entity to block or boost, but as a system of variants that can be individually tuned.

How BCLAF1 Itself Is Regulated

Understanding what controls BCLAF1 levels is just as important as understanding what BCLAF1 does, because many disease processes hinge on whether there is too much or too little of it. The protein is regulated at multiple levels. At the protein stability level, BCLAF1’s interaction with Hsp90α protects it from degradation; disrupting that interaction with a compound called novobiocin causes BCLAF1 to be tagged for destruction by the proteasome.⁹ Viruses exploit a version of this same vulnerability when they redirect the proteasome to chew up BCLAF1 during infection.

At the RNA level, microRNAs serve as natural brakes on BCLAF1 production. In bladder cancer, for instance, miR-194-5p normally suppresses BCLAF1, but the long non-coding RNA PVT1 sponges up that microRNA, effectively releasing the brake and letting BCLAF1 levels climb.¹¹ Caspase-10 provides yet another layer of control by directly cleaving BCLAF1 to limit its autophagy-inducing activity.¹ The sheer number of regulatory mechanisms reflects how much the cell’s health depends on getting BCLAF1 levels right.

Why Context Determines Everything

The recurring theme in BCLAF1 research is that the same protein can be beneficial or harmful depending on the circumstances. In a healthy cell facing DNA damage, BCLAF1 helps repair the breaks and, if the damage is too severe, pushes the cell toward death. Both outcomes protect the organism. In a cancer cell, those same abilities become liabilities for the patient: DNA repair lets the tumor survive radiation, and altered splicing drives aggressive growth. In the immune system, BCLAF1 is essential for activating the interferon response against viruses, which is precisely why herpesviruses have evolved such efficient ways to destroy it.

This context-dependence makes BCLAF1 a genuinely difficult therapeutic target. Simply blocking it across the board would impair DNA repair and antiviral immunity in healthy tissues. Simply boosting it might fuel tumors that already overexpress it. The most promising approaches, like the splice-switching compounds tested in colorectal cancer, try to thread this needle by targeting specific BCLAF1 variants or specific regulatory interactions rather than the protein as a whole. Whether that precision can translate from laboratory cell cultures to effective treatments in patients remains an open question, but BCLAF1 has moved from an obscure apoptosis-associated factor to a protein that researchers across oncology, virology, and immunology are watching closely.

1
International Journal of Biological Sciences. Caspases: A Molecular Switch Node in the Crosstalk between Autophagy and Apoptosis
2
PubMed Central. BCLAF1 is a radiation-induced H2AX-interacting partner involved in γH2AX-mediated regulation of apoptosis and DNA repair
3
PubMed. BCLAF1, a functional partner of BACH1, participates in DNA damage response
4
PubMed Central. The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export
5
bioRxiv. BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia
6
PubMed Central. Function of BCLAF1 in human disease
7
PubMed Central. BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex
8
Life Sciences. BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma
9
PubMed Central. Heat Shock Protein 90α-Dependent B-Cell-2-Associated Transcription Factor 1 Promotes Hepatocellular Carcinoma Proliferation by Regulating MYC Proto-Oncogene c-MYC mRNA Stability
10
Cancer Management and Research. Role of Bclaf1 in Promoting Adrenocortical Carcinoma Proliferation: A Study Combining the Use of Bioinformatics and Molecular Events
11
PubMed Central. LncRNA PVT1 accelerates malignant phenotypes of bladder cancer cells by modulating miR-194-5p/BCLAF1 axis as a ceRNA
12
PubMed Central. BCL2-Associated Transcription Factor 1 Promotes SRC/Hypoxia-Inducible Factor 1 Subunit α-Mediated Cancer Stemness in Radioresistant Triple-Negative Breast Cancer
13
PubMed Central. BclAF1 restriction factor is neutralized by proteasomal degradation and microRNA repression during human cytomegalovirus infection
14
PubMed Central. Bclaf1 critically regulates the type I interferon response and is degraded by alphaherpesvirus US3
15
NAR Cancer. A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells